Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials

BACKGROUND AND OBJECTIVES: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders. These analyses characterized the population pharmacokinetics of upa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacokinet
Autori principali: Klünder, Ben, Mittapalli, Rajendar K., Mohamed, Mohamed-Eslam F., Friedel, Anna, Noertersheuser, Peter, Othman, Ahmed A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2019
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6614152/
https://ncbi.nlm.nih.gov/pubmed/30945116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-019-00739-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi